| Literature DB >> 26687971 |
Anam Anzak1, Huiling Tan2, Alek Pogosyan2, Sadaquate Khan3, Shazia Javed3, Steven S Gill3, Keyoumars Ashkan4, Harith Akram4, Thomas Foltynie5, Patricia Limousin5, Ludvic Zrinzo5, Alexander L Green5, Tipu Aziz5, Peter Brown6.
Abstract
Enhancements in motor performance have been demonstrated in response to intense stimuli both in healthy subjects and in the form of 'paradoxical kinesis' in patients with Parkinson's disease. Here we identify a mid-latency evoked potential in local field potential recordings from the region of the subthalamic nucleus, which scales in amplitude with both the intensity of the stimulus delivered and corresponding enhancements in biomechanical measures of maximal handgrips, independent of the dopaminergic state of our subjects with Parkinson's disease. Recordings of a similar evoked potential in the related pedunculopontine nucleus - a key component of the reticular activating system - provide support for this neural signature in the subthalmic nucleus being a novel correlate of ascending arousal, propagated from the reticular activating system to exert an 'energizing' influence on motor circuitry. Future manipulation of this system linking arousal and motor performance may provide a novel approach for the non-dopaminergic enhancement of motor performance in patients with hypokinetic disorders such as Parkinson's disease.Entities:
Keywords: Arousal; Evoked activity; Local field potentials; Pedunculopontine nucleus; Subthalamic nucleus
Mesh:
Substances:
Year: 2015 PMID: 26687971 PMCID: PMC4767325 DOI: 10.1016/j.expneurol.2015.12.004
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.330
Patient details. Surgical sites: (1) National Hospital for Neurology & Neurosurgery, London, (2) John Radcliffe Hospital, Oxford, (3) Kings College Hospital, London, (4) Frenchay Hospital, Bristol. UPDRS scores for Patient 8 were not available.
| Site | Bilateral targets | Patient no. | Age/yrs | Disease duration/yrs | Daily L-DOPA equivalent dose/mg | Pre-op UPDRS OFF/ON Levodopa |
|---|---|---|---|---|---|---|
| 1 | STN | 1 | 59 | 15 | 700 | 28/5 |
| 1 | STN | 2 | 60 | 17 | 1725 | 63/7 |
| 1 | STN | 3 | 32 | 10 | 875 | 52/13 |
| 1 | STN | 4 | 56 | 10 | 400 | 40/12 |
| 2 | STN | 5 | 70 | 12 | 1100 | 62/29 |
| 2 | STN | 6 | 60 | 7 | 200 | 25/13 |
| 3 | STN | 7 | 56 | 10 | 900 | 26/7 |
| 3 | STN | 8 | 64 | 12 | 300 | n/a |
| 4 | STN& PPN | 9 | 68 | 12 | 475 | 38/20 |
Fig. 1Normalized group average (A) grip force (B) reaction times, in response to five different cue intensities averaged across OFF and ON L-DOPA recordings. n = 16 gripping hands. Traces in (A) have been normalized as a percentage of the maximal peak force attained among different trials by an individual in response to the maximum intensity stimulus, before collation across subjects. Shaded area corresponding to each cue intensity represents the 95% confidence interval (CI) of the force traces. Note, where the CIs overlap, the CI of the greater amplitude trace is shown. Group mean RTs are shown with SEM.
Results of repeated measures ANOVAs with factors (1) stimulus intensity (82, 88, 94, 100 and 105 dB) and (2) medication state (OFF and ON dopaminergic medication), applied to peak force and reaction time data. n = 16 gripping hands. Significant values are emboldened. The greater peak forces attained by subjects in OFF medication compared to those in ON likely reflect a fatigue effect in ON drug recordings which wereundertaken secondly.
| Peak force | Reaction time | |
|---|---|---|
| Stimulus intensity | F4,60 = 3.369 | F4,60 = 4.487 |
| Medication state | F1,15 = 5.357 | F1,15 = 0.004 |
| Stimulus intensity ∗ medication state | F4,60 = 0.584 | F4,60 = 0.382 |
Fig. 2Group average STNr mid-latency evoked potentials in response to five different cue intensities, averaged across OFF and ON L-DOPA recordings. n = 16 STNr. Shaded area corresponding to each cue intensity represents the 95% CI of the evoked potential, and where the CIs overlap, the CI of the greater amplitude trace is shown. The absolute amplitude of the evoked potential is shown as a z-score (see Materials and methods).
Results of separate repeated measures ANOVAs for OFF and ON L-DOPA recordings applied to each individual's mean peak evoked potential amplitudes, with factors (1) stimulus intensity (82, 88, 94, 100 and 105 dB) and (2) hemisphere (left versus right STNr) (n = 16 experimental runs). Significant values are emboldened.
| OFF L-DOPA | ON L-DOPA | |
|---|---|---|
| Stimulus intensity | F4,60 = 7.365 | F4,60 = 5.766 |
| STNr side | F1,15 = 0.441 | F1,15 = 0.002 |
| Stimulus intensity ∗ STNr side | F4,60 = 0.660 | F4,60 = 1.484 |
Fig. 3Scatter-plots relating increases in average absolute peak evoked potential amplitude to enhancements in (A) peak force and (B) reaction time, relative to the average of peak responses to the lowest intensity imperative cues. Data are derived from the remaining four sound intensities in the eight subjects. Solid lines represent best-fit lines fitted by simple linear regression. Dashed lines represent 95% CI of the regression line.
Fig. 4Average evoked potentials recorded simultaneously in (A) PPNr and (B) STNr. Traces represent the grand averages of recordings from left and right nuclei of a single patient whilst OFF and ON L-DOPA. Normalization technique and CI representation are as in Fig. 2. Dashed vertical line denotes the common onset latency of the first evoked potential in both structures.
Fig. 5Average peak amplitude of the absolute evoked potentials recorded from the PPNr, in response to five different cue intensities. n = 2 PPNr, one individual. Average responses in experimental runs when the patient was OFF followed by ON their normal antiparkinsonian medication (L-DOPA) are shown. Error bars represent SEM of recordings averaged across all contact pairs in left and right PPN DBS electrodes. Evoked potential amplitudes were normalized to the greatest amplitude peak across the trials recorded in response to the lowest intensity stimulus, for each PPN, before averaging across sides.